Welcome to the new morningstar.co.uk! Learn more about the changes and how our new features help your investing success.

Glaxo Submits Japanese Application For Daprodustat Anaemia Drug

(Alliance News) - GlaxoSmithKline PLC on Wednesday said it has submitted a new drug application ...

Alliance News 21 August, 2019 | 8:38AM
Email Form

(Alliance News) - GlaxoSmithKline PLC on Wednesday said it has submitted a new drug application in Japan for anaemia drug daprodustat.

The application was submitted to the Japanese Ministry of Health, Labour & Welfare for the approval of daprodustat as a treatment for patients with renal anaemia resulting from chronic kidney disease.

Chronic kidney disease patients are often anaemic as their kidneys do not make enough erythropoietin, which is "a hormone involved in prompting the production of red blood cells".

Daprodustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor, a new class of drugs which encourage the bone marrow to increase red blood cell production. As present, the drug has not been approved for renal anaemia or any other condition.

Hal Barron, chief scientific officer and president of Research & Development at Glaxo, said: "Around 3.5 million patients in Japan have anaemia associated with renal disease which can result in weakness and fatigue. We are excited about our first regulatory filing for daprodustat which, if approved, will provide a new and convenient oral treatment option for these patients."

Shares in Glaxo were down 0.1% at 1,664.70 pence in London on Wednesday morning.

By Anna Farley; annafarley@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
GlaxoSmithKline PLC 1,645.20 GBX 1.11

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites